| Literature DB >> 22674247 |
Yinghu Chen1, Shiqiang Shang, Yongmin Tang, Chenmei Zhang, Meiqin Tong, Yuwen Dai.
Abstract
OBJECTIVE: To highlight the clinical presentations of influenza A (H1N1) infection, for early diagnosis and recognition by the pediatricians.Entities:
Mesh:
Year: 2012 PMID: 22674247 PMCID: PMC7101651 DOI: 10.1007/s12098-012-0784-y
Source DB: PubMed Journal: Indian J Pediatr ISSN: 0019-5456 Impact factor: 1.967
Fig. 1Age-specific cumulative number for confirmed hospitalized cases, by risk factors, by month age groups, from November 1, 2009–May 31, 2011 (n = 80)
Time from onset of symptoms to admission to hospital, laboratory confirmation, admission to ICU, receive antiviral therapy, stop shedding virus and length of stay associated with pandemic influenza A
| Time period | Cases N | Mean (d) | Median (d) | Min (d) | Max (d) |
|---|---|---|---|---|---|
| Onset of symptoms to admission to hospital* | 70 | 6.0 | 5 | 1 | 20 |
| Onset of symptoms to laboratory confirmation** | 80 | 6.4 | 5 | 1 | 20 |
| Length of stay in hospital * | 70 | 10.7 | 9 | 2 | 32 |
| Onset of symptoms to admission to ICU | 24 | 7.1 | 7 | 1 | 15 |
| Length of stay in ICU | 24 | 7.6 | 6 | 1 | 24 |
| Length of ventilator support | 10 | 10.4 | 8.5 | 4 | 19 |
| Admission to receive antiviral therapy (Oseltamivir) | 67 | 1.7 | 1 | 1 | 12 |
| Onset of symptoms to receive antiviral therapy (Oseltamivir) | 67 | 6.9 | 6 | 1 | 18 |
| Length of shedding virus † | 41 | 11.4 | 11 | 2 | 21 |
| Pyretolysis after receiving oseltamivir | 46 | 2.7 | 1 | 1 | 28 |
ICU Intensive care unit
* Ten cases were excluded because they were nosocomial influenza A virus infection
** Time to laboratory confirmation is longer than time to admission, reflecting the time taken for laboratory confirmation
† Length of virus shedding was calculated as the time from onset of symptoms to the first date of 3 d of continuous negativity
Radiographic and laboratory findings, complications and concurrent infection for influenza A (H1N1)
| Admission characteristics | Pandemic Influenza A cohort | ||
|---|---|---|---|
| Hospitalized patients * | ICU patients | ||
| WBC (×109/L), n (%) | >12 | 20 (25) | 6 (25.5) |
| <4 | 20 (25) | 9 (37.5) | |
| Chest X-Ray, n (%) | Pattern | Patching: 42 (52.5) | Patching: 7 (29.2) |
| Consolidation: 28 (35) | Consolidation: 17 (70.8) | ||
| Increase in lung marking:10 (12.5) | |||
| Extent >20 % | 26 (32.5) | 18 (75) | |
| Unilateral | 5 (6.3) | 2 (8.3) | |
| Bilateral | 24 (30) | 16 (66.7) | |
| CRP (>8 mg/L), n (%) | 28 (35) | 13 (54.2) | |
| Administered antibiotics before admission, n (%) | 71 (88.8) | 20 (83.3) | |
| Concurrent infection, n | RSV 9, Mp 6, Cp 3, Parainfluenza 1, CMV 2, MRSE 4, MRSH 1,K. Pneumonia 1, A.baumanii 1 | MRSE 1, MRSH 1,K. Pneumonia 1, Parainfluenza 1, Mp 2, RSV 1 | |
| Complications, n | ARDS 11; Pneumothorax 8; Encephalopathy 8; Pleural effusion 7; Atelactasis 4; Renal failure 4; Sepsis 3; Pulmonary fibrosis 2; Mediastinal hernia 2; Infectious endocarditis 1 Reye’s Syndrome, 1 | ARDS 11; Pneumothorax 7; Encephalopathy 4; Renal failure 4; Atelectasis 3; Pleural effusion 3 Pulmonary fibrosis 2; Mediastinal hernia 2; Infectious endocarditis 1 Reye’s syndrome 1 | |
| Th1/Th2 cytokines↑ n/N (%) | 11/38 (28.9) | 7/21 (30) | |
ICU Intensive care unit; WBC White blood cells count; CRP C-reactive protein; RSV Respiratory syncytial virus; Mp Mycoplasma pneumonia; Cp Chlamydia pneumonia; CMV Cytomegalovirus; MRSE Methicillin resistant Staphylococcus epidermidis; MSSE Methicillin sensible Staphylococcus epidermidis; MRSH Methicillin resistant staphylococcus hominis; ARDS Acute respiratory distress syndrome;
* ICU cases are included in hospitalized case count